Impact of Androgen Deprivation Therapy on Self-Reported Cognitive Function in Men with Prostate Cancer
- PMID: 29477720
- DOI: 10.1016/j.juro.2018.02.073
Impact of Androgen Deprivation Therapy on Self-Reported Cognitive Function in Men with Prostate Cancer
Abstract
Purpose: Although androgen deprivation therapy is widely used to treat prostate cancer, its effects on cognitive function are unclear. To our knowledge no prior report has examined the impact of androgen deprivation therapy on self-reported cognitive function.
Materials and methods: Three groups of men 50 years old or older who were matched on age and education were enrolled in the study, including 81 with prostate cancer starting on continuous androgen deprivation therapy, 84 controls with prostate cancer not receiving androgen deprivation therapy and 85 healthy controls. Two scales from the FACT-Cog (Functional Assessment of Cancer Therapy-Cognitive subscale) version 3 were used to assess self-reported cognitive function. Changes in cognitive scores with time were analyzed by 2 approaches, including 1) multivariable regression and 2) calculation of the proportion of subjects per group with a decrease of 1 SD or more. Multivariable regression was applied to assess predictors of a decline in self-reported cognitive function. We also examined relationships between the FACT-Cog and a neuropsychological battery of 15 tests.
Results: Mean participant age was 69 years (range 50 to 87). The mean educational level was 15 years (range 8 to 24). FACT-Cog scores were similar at baseline across the cohorts. Neither analytical approach revealed that androgen deprivation therapy was associated with changes in self-reported cognitive function on either FACT-Cog scale. Mood and fatigue correlated with changes in self-reported cognitive function. The relationship between self-reported and objective cognitive measures was weak (maximum Spearman correlation coefficient 0.14) and only 2 of 30 correlations were statistically significant.
Conclusions: A total of 12 months of androgen deprivation therapy were not associated with self-reported cognitive function changes in older men with nonmetastatic prostate cancer.
Keywords: androgen antagonists; cognitive dysfunction; prostatic neoplasms; quality of life; surveys and questionnaires.
Copyright © 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Comment in
-
Editorial Comment.J Urol. 2018 Aug;200(2):334. doi: 10.1016/j.juro.2018.02.3112. Epub 2018 Apr 25. J Urol. 2018. PMID: 29702060 Free PMC article. No abstract available.
Similar articles
-
Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer.J Urol. 2006 Dec;176(6 Pt 1):2443-7. doi: 10.1016/j.juro.2006.07.151. J Urol. 2006. PMID: 17085125
-
Impact of androgen deprivation therapy on weight gain differs by age in men with nonmetastatic prostate cancer.J Urol. 2012 Dec;188(6):2183-8. doi: 10.1016/j.juro.2012.08.018. Epub 2012 Oct 18. J Urol. 2012. PMID: 23083859
-
Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer.Cancer. 2017 Jan 1;123(2):237-244. doi: 10.1002/cncr.30320. Epub 2016 Sep 1. Cancer. 2017. PMID: 27583806
-
Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review.J Clin Oncol. 2014 Feb 1;32(4):335-46. doi: 10.1200/JCO.2013.49.5523. Epub 2013 Dec 16. J Clin Oncol. 2014. PMID: 24344218 Review.
-
Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.JAMA Oncol. 2015 Dec;1(9):1261-9. doi: 10.1001/jamaoncol.2015.2895. JAMA Oncol. 2015. PMID: 26378418 Review.
Cited by
-
A Comprehensive Review and Androgen Deprivation Therapy and Its Impact on Alzheimer's Disease Risk in Older Men with Prostate Cancer.Degener Neurol Neuromuscul Dis. 2024 May 17;14:33-46. doi: 10.2147/DNND.S445130. eCollection 2024. Degener Neurol Neuromuscul Dis. 2024. PMID: 38774717 Free PMC article. Review.
-
Psychosocial Factors Associated with Cognitive Function in Prostate Cancer Survivors on Hormonal Treatments: A Systematic Review.Neuropsychol Rev. 2024 Apr 20. doi: 10.1007/s11065-024-09639-1. Online ahead of print. Neuropsychol Rev. 2024. PMID: 38642173 Review.
-
A review of the objective cognitive function measurements in males receiving hormonal therapy for prostate cancer.Investig Clin Urol. 2023 Nov;64(6):521-540. doi: 10.4111/icu.20230103. Investig Clin Urol. 2023. PMID: 37932563 Free PMC article. Review.
-
[Testosterone and Alzheimer's disease].Probl Endokrinol (Mosk). 2022 Jun 24;68(5):97-107. doi: 10.14341/probl13136. Probl Endokrinol (Mosk). 2022. PMID: 36337024 Free PMC article. Russian.
-
Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors.CNS Drugs. 2022 May;36(5):419-449. doi: 10.1007/s40263-022-00913-5. Epub 2022 May 6. CNS Drugs. 2022. PMID: 35522374 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical